A new trading day began on Monday, with Arbutus Biopharma Corp (NASDAQ: ABUS) stock price down -3.30% from the previous day of trading, before settling in for the closing price of $3.64. ABUS’s price has ranged from $1.75 to $4.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 55.33% over the past five years. Meanwhile, its annual earnings per share averaged 11.82%. With a float of $147.22 million, this company’s outstanding shares have now reached $169.87 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees. In terms of profitability, gross margin is 84.13%, operating margin of -1223.89%, and the pretax margin is -1137.64%.
Arbutus Biopharma Corp (ABUS) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arbutus Biopharma Corp is 22.31%, while institutional ownership is 53.46%. The most recent insider transaction that took place on Aug 14 ’24, was worth 32,637. In this transaction Director of this company sold 8,846 shares at a rate of $3.69, taking the stock ownership to the 46,069 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Medical Officer sold 4,358 for $2.31, making the entire transaction worth $10,078. This insider now owns 125,542 shares in total.
Arbutus Biopharma Corp (ABUS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 11.82% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Here are Arbutus Biopharma Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 99.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 1.09 million, a negative change from its year-to-date volume of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 22.54%. Additionally, its Average True Range was 0.16.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 30.55%, which indicates a significant increase from 16.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.78% in the past 14 days, which was lower than the 38.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.96, while its 200-day Moving Average is $3.37. Nevertheless, the first resistance level for the watch stands at $3.64 in the near term. At $3.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.83. If the price goes on to break the first support level at $3.45, it is likely to go to the next support level at $3.37. Assuming the price breaks the second support level, the third support level stands at $3.26.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
With a market capitalization of 668.85 million, the company has a total of 189,492K Shares Outstanding. Currently, annual sales are 18,140 K while annual income is -72,850 K. The company’s previous quarter sales were 1,340 K while its latest quarter income was -19,720 K.
